PE20142113A1 - Analogos de glucagon - Google Patents
Analogos de glucagonInfo
- Publication number
- PE20142113A1 PE20142113A1 PE2014000970A PE2014000970A PE20142113A1 PE 20142113 A1 PE20142113 A1 PE 20142113A1 PE 2014000970 A PE2014000970 A PE 2014000970A PE 2014000970 A PE2014000970 A PE 2014000970A PE 20142113 A1 PE20142113 A1 PE 20142113A1
- Authority
- PE
- Peru
- Prior art keywords
- ser
- leu
- lys
- asp
- absent
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA R1-X-Z-R2 O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE R1 ES H, ALQUILO C1-C4, ACETILO, ENTRE OTROS; R2 ES OH O NH2; X ES UN PEPTIDO QUE TIENE LA SIGUIENTE FORMULA: HIS-X2-X3-GLY-THR-PHE-THR-SER-ASP-TYR-SER-X12-TYR-LEU-ASP-X16-ARG-ARG-ALA-X20-ASP-PHE-ILE-X24-TRP-LEU-X27-X28-X29 EN LA QUE X2 ES SER, D-SER O AIB; X3 ES GLN, HIS O PRO; X12 ES LYS O Y; X16 ES GLU O Y; X20 ES LYS O Y; X24 ES GLU O Y; X27 ES LEU O Y; X28 ES SER, Y O ESTA AUSENTE; X29 ES ALA O ESTA AUSENTE; CADA RESTO Y ESTA PRESENTE Y SE SELECCIONA DE LYS, CYS Y ORN. Z ESTA AUSENTE O ES UNA SECUENCIA DE 1 A 20 AMINOACIDOS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN ANALOGO DEL GLUCAGON CON SELECTIVIDAD AUMENTADA PARA EL RECEPTOR DE GLP-1. UTIL EN EL TRATAMIENTO DE LA OBESIDAD Y DIABETES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579888P | 2011-12-23 | 2011-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142113A1 true PE20142113A1 (es) | 2014-12-03 |
Family
ID=47594620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000970A PE20142113A1 (es) | 2011-12-23 | 2012-12-19 | Analogos de glucagon |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130316941A1 (es) |
| EP (1) | EP2793931A2 (es) |
| JP (1) | JP2015502380A (es) |
| KR (1) | KR20140114845A (es) |
| CN (1) | CN104144696A (es) |
| AP (2) | AP2014007797A0 (es) |
| AU (1) | AU2012357739A1 (es) |
| BR (1) | BR112014015681A2 (es) |
| CA (1) | CA2858949A1 (es) |
| EA (1) | EA201490982A1 (es) |
| HK (1) | HK1200369A1 (es) |
| IL (1) | IL232800A0 (es) |
| IN (1) | IN2014CN04401A (es) |
| MA (1) | MA35864B1 (es) |
| MX (1) | MX2014007120A (es) |
| PE (1) | PE20142113A1 (es) |
| PH (1) | PH12014501336A1 (es) |
| SG (1) | SG11201403377QA (es) |
| TN (1) | TN2014000224A1 (es) |
| WO (1) | WO2013092703A2 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MA34383B1 (fr) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | Analogues de glucagon |
| AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
| EP2664374A1 (en) * | 2012-05-15 | 2013-11-20 | F. Hoffmann-La Roche AG | Lysin-glutamic acid dipeptide derivatives |
| TWI642682B (zh) | 2012-07-23 | 2018-12-01 | 丹麥商西蘭製藥公司 | 升糖素類似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| DK3057984T3 (en) | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| TWI670281B (zh) | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法 |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐアゴニスト化合物及び方法 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| EP3673900B1 (en) | 2015-02-17 | 2025-06-25 | Amphastar Pharmaceuticals, Inc. | Nasal powder formulation for treatment of hypoglycemia |
| CA2979950A1 (en) | 2015-03-18 | 2016-09-22 | Zealand Pharma A/S | Amylin analogues |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| RU2735762C2 (ru) * | 2015-04-16 | 2020-11-06 | Зилэнд Фарма А/С | Ацилированный аналог глюкагона, его применение и способы получения |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| EP3468569A4 (en) | 2016-06-09 | 2020-05-27 | AmideBio LLC | GLUCAGON ANALOGS AND METHODS OF USING THE SAME |
| WO2018024653A1 (en) | 2016-08-05 | 2018-02-08 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| JP6563614B1 (ja) * | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア／エス | アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| ES2973986T3 (es) * | 2017-08-16 | 2024-06-25 | Dong A St Co Ltd | Análogo peptídico acilado de oxintomodulina |
| CA3087827A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| KR20200116978A (ko) | 2018-02-02 | 2020-10-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체 |
| BR112020014436A2 (pt) | 2018-02-02 | 2020-12-01 | Boehringer Ingelheim International Gmbh | derivados de triazolopirimidina, composição farmacêutica e seus usos como inibidores de grelina o-acil transferase (goat) |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CN111349155B (zh) * | 2018-12-24 | 2022-04-05 | 浙江和泽医药科技股份有限公司 | 一种胰高血糖素类似物及其制备方法和用途 |
| TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
| CN115916789B (zh) | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| ES2984466T3 (es) | 2020-05-22 | 2024-10-29 | Boehringer Ingelheim Int | Procedimiento de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
| CN113292646B (zh) * | 2020-05-29 | 2022-05-13 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| JP2008543816A (ja) | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | 新規化合物および該化合物が摂食行動に及ぼす効果 |
| CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| CN101622276B (zh) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CL2009001424A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. |
| AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| EA020596B1 (ru) * | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| AU2010272944B2 (en) * | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AU2011206979B2 (en) * | 2010-01-20 | 2015-09-10 | Zealand Pharma A/S | Treatment of cardiac conditions |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/pt not_active IP Right Cessation
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/xx unknown
- 2012-12-19 EA EA201490982A patent/EA201490982A1/ru unknown
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/zh active Pending
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/ja active Pending
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/xx unknown
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/ko not_active Withdrawn
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/es unknown
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/es not_active Application Discontinuation
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
-
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/xx unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/fr unknown
-
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1200369A1 (en) | 2015-10-09 |
| CN104144696A (zh) | 2014-11-12 |
| AU2012357739A1 (en) | 2014-07-03 |
| TN2014000224A1 (en) | 2015-09-30 |
| WO2013092703A3 (en) | 2013-11-14 |
| IN2014CN04401A (es) | 2015-09-04 |
| CA2858949A1 (en) | 2013-06-27 |
| MX2014007120A (es) | 2015-03-05 |
| EA201490982A1 (ru) | 2015-01-30 |
| SG11201403377QA (en) | 2014-07-30 |
| IL232800A0 (en) | 2014-07-31 |
| PH12014501336A1 (en) | 2014-09-15 |
| EP2793931A2 (en) | 2014-10-29 |
| US20130316941A1 (en) | 2013-11-28 |
| AP2014007774A0 (en) | 2014-07-31 |
| WO2013092703A2 (en) | 2013-06-27 |
| BR112014015681A2 (pt) | 2019-09-24 |
| KR20140114845A (ko) | 2014-09-29 |
| AP2014007797A0 (en) | 2014-07-31 |
| JP2015502380A (ja) | 2015-01-22 |
| MA35864B1 (fr) | 2014-12-01 |
| US20160347813A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142113A1 (es) | Analogos de glucagon | |
| AR094180A1 (es) | Derivados de exendina-4 | |
| AR098739A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) | |
| AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
| PE20130326A1 (es) | Analogos de glucagon | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| AR098740A1 (es) | Análogos del péptido exendina-4 | |
| PE20130338A1 (es) | Analogos del glucagon | |
| PE20140969A1 (es) | Combinacion de analogos del glucagon acilados con analogos de insulina | |
| AR091866A1 (es) | Analogos del glucagon | |
| AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
| TN2012000215A1 (en) | Pharmaceutical compositions comprising a g l p -1 agonist and methionine | |
| AR096440A1 (es) | Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip) | |
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| AR104932A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| NZ589847A (en) | Glucagon/glp-1 receptor co-agonists | |
| PE20121130A1 (es) | Analogos de glucagon acilados | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| MX366405B (es) | Uso de peptidos glp-1 de accion prolongada. | |
| NI201100213A (es) | Péptidos específicos para receptores de melanocortina | |
| MX369259B (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| PE20140724A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| MX377410B (es) | Antagonistas de receptores de integrina y sus metodos de uso. | |
| PH12014500923A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |